Dr Tamara Maiuri
Hamilton, Ontario, Canada
Dr. Tamara Maiuri is a postdoctoral fellow in Dr. Ray Truant's group at McMaster University, Canada. Prior to joining the Huntington's disease field, Tamara obtained her PhD from the Medical Biophysics Department at the University of Toronto where she studied the cell biology of cancer-related genes. Her work in the Truant lab focuses on the normal biological functions of the huntingtin protein in hopes of understanding how they may be disrupted upon inheritance of the mutant huntingtin gene that causes HD.
Articles edited by Dr Tamara Maiuri
- Update on the PTC Therapeutics PIVOT-HD Trial
- Exciting new Huntingtin lowering tool described
- Fresh Updates from First Huntingtin Lowering Study Publication
- An Updated Trial Design for Roche's Huntingtin Lowering Trial
- Advances on many fronts in the battle against the protein that causes Huntington's disease
- An early role for the Huntington's disease gene – but don't believe all the headlines
- New interest in an old target
- Success! ASO drug reduces levels of mutant protein in Huntington's disease patients
- Update confirms Huntington's disease 'gene silencing' trial on track
- Precision huntingtin-lowering drug trials target the mutant protein
- New study reveals a potential HD biomarker
- FDA approves a new drug for symptoms of Huntington's disease
- Treasure your exceptions - using outliers to understand Huntington's disease onset and progression
- Early exposure to the HD protein may cause life-long symptoms
- Thinking clearly about the earliest symptoms of HD and which brain regions control them
- How NOT to write a news article about a clinical trial
- Liftoff: First humans treated with gene silencing drugs for HD!
- Measuring harmful huntingtin protein in the brain’s bath water
- Novel research technique suggests an antioxidant gene protects vulnerable neurons
- Taking new targets to the bank: the DNA repair protein ‘ATM’ is overactive in Huntington's disease
- Unlocking the Potential of Antibodies as a Therapy for Huntington’s Disease
- Huntington's disease clinical trial announcement: huntingtin-lowering drug to enter Phase I trial in 2015
- New results bring BDNF therapies into focus
- HD mice provide a useful failure
- NUB1: enhancing clearance to decrease mutant huntingtin
- Could HD be caused by amino acid deficiency?
Articles written by Dr Tamara Maiuri
- Huntington’s disease therapeutics conference 2023 - Day 3
- Huntington’s disease therapeutics conference 2023 - Day 2
- Huntington’s disease therapeutics conference 2023 - Day 1
- Could molecular handcuffs lower the protein that causes Huntington's disease?
- Illuminating the progression of Huntington’s disease
- More evidence points to Huntington's disease exercise benefit
- Splicing with danger: a new way of thinking about the harmful Huntington's disease protein
- Is a new technique set to revolutionize Huntington's disease genetic testing?
- Dyeing to prevent dying? Methylene blue beneficial in Huntington's disease mice
- HDBuzz Prize runner-up 2012: Fruit flies, faulty connections and Huntington's disease